drugset / Trial / NCT04196998

Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis

NCT04196998

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is to investigate the clinical efficacy and safety of three types of nucleotide/nucleoside analogues in treatment of hepatitis b virus related compensated cirrhosis.

Timeline

Start
2019-01-01
Primary completion
2023-12
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Entecavir Small molecule 0.5 mg Oral
Comparator Tenofovir disoproxil fumarate Small molecule 300 mg Oral
Subject tenofovir alafenamide Small molecule 25 mg Oral